Evidence map›Paper›PMID 34213706›Full record

ArticleJournal of neuro-oncology2021

The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients.

Peter Taule-Sivertsen, Ove Bruland, Aril Løge Håvik, Eirik Bratland, Morten Lund-Johansen, Per Morten Knappskog

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. TANC1::HTRA1 fusion in schwannomas.Brain pathology (Zurich, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. A Critical Overview of Targeted Therapies for Vestibular Schwannoma.International journal of molecular sciences · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Peter Taule-SivertsenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Ove BrulandDepartment of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Aril Løge HåvikDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Eirik BratlandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Morten Lund-JohansenDepartment of Clinical Science, University of Bergen, Bergen, Norway. morten.lund-johansen@helse-bergen.no.ORCID http://orcid.org/0000-0002-4331-7812
Per Morten KnappskogDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVestibular schwannoma (VS) is a benign intracranial tumor in which the underlying genetics is largely uncertain, apart from mutations in the tumor suppressor gene NF2. Alternative tumorigenic mechanisms have been proposed, including a recurrent in-frame fusion transcript of the HTRA1 and SH3PXD2A genes. The gene product of the SH3PXD2A-HTRA1 fusion has been shown to promote proliferation, invasion and resistance to cell death in vitro and tumor growth in vivo. The aim of this study was to replicate the findings and to investigate the frequency of this fusion gene in another cohort of vestibular schwannoma patients.

methodsThe SH3PXD2A-HTRA1 transcript was synthesized in vitro using PCR and used as a positive control to assess the sensitivity of a real-time PCR assay. This real-time PCR assay was used to search for the presence of the fusion transcript in 121 Norwegian sporadic VS patients.

resultsThe real-time PCR assay showed a high sensitivity and was able to detect as low as ~ 5 copies of the fusion transcript. Out of the 121 investigated tumors, only 1 harbored the SH3PXD2A-HTRA1 fusion.

conclusionEven though the SH3PXD2A-HTRA1 fusion has been shown to be a driver of tumorigenesis, our results suggest that it is a rare event in our VS patients. Further investigation is warranted in order to elucidate whether our results represent an extreme, and if the fusion is present also in other neoplasms.

Indexed as

Adaptor Proteins, Vesicular TransportHigh-Temperature Requirement A Serine Peptidase 1Neuroma, AcousticOncogene Proteins, FusionHumansNorwayAdaptor Proteins, Vesicular TransportHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanOncogene Proteins, FusionSH3PXD2A protein, humanDriver mutationGene fusionGeneticsNeurosurgeryTumorigenesisVestibular schwannoma

Identifiers

PMID34213706
PMCPMC8367919
OpenAlexW3175880373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.